ATLANTA--(BUSINESS WIRE)--A new analysis of diabetes, peripheral artery disease (PAD) and critical limb ischemia (CLI) in Mexico published by THE SAGE GROUP projects that the number of Mexicans with PAD will exceed 7 million by 2030.
“Mexico is experiencing three interrelated epidemics: diabetes, PAD and CLI,” stated Mary L. Yost, President of THE SAGE GROUP. “The diabetes epidemic combined with the aging population, is driving the growth of PAD and CLI.”
“Age and diabetes are two significant risk factors for PAD,” Yost explained. “In addition, diabetes in Mexico is characterized by factors that predispose the population to long-term cardiovascular complications, including PAD, CLI and amputations.”
“Over the last 20 years, the prevalence of diabetes in Mexico has more than doubled. According to the International Diabetes Foundation (IDF) Mexico is the 6th most diabetic country in the world,” she continued.
Discussing the impact of diabetes on CLI and amputation, Ms. Yost stated, “Diabetes increases the severity of CLI, elevates the risk of amputation by 28 times and as the severity of diabetes increases amputation risk rises. We estimate that 86,000-134,000 CLI-related amputations occur in Mexico.”
On October 31, 2014 Ms. Yost presented the results of the Mexican research at the XLVI National Congress of Angiology and Vascular Surgery held in Guadalajara, Jalisco Mexico.
About the Report: Mexico, Diabetes, Peripheral Artery Disease and Critical Limb Ischemia.
The report contains a comprehensive analysis of diabetes and other cardiovascular risk factors in Mexico. PAD and CLI prevalence is estimated for 2010 and projected through 2030. Estimates of the number of diabetic foot ulcers (DFUs), ischemic DFUs and CLI-related amputations in Mexico are also included.
PAD and CLI are estimated according to the Diabetes Method, a population-based projection model developed by THE SAGE GROUP. The Diabetes Method has been employed to estimate PAD in the U.S., Canada, major markets of Western Europe, India and South America.
About THE SAGE GROUP
THE SAGE GROUP, a research and consulting company, specializes in atherosclerotic disease in the lower limbs, specifically PAD, IC, CLI and ALI (Acute Limb Ischemia) as well as ischemic DFU and dysvascular amputation. Recent research focuses on quantifying the economic and social costs of PAD and amputation.
